It has been recently published that reduced BRCA1 expression correlates with a better outcome following platinum chemotherapy, and clinical trials report on significant anti-tumour activity following PARP inhibitor treatment in BRCA1-deficient patients. The gene discussed is PARP1; the disease is neoplasm.